New publication about the treatment of triple-class refractory multiple myeloma in Spain

//New publication about the treatment of triple-class refractory multiple myeloma in Spain

New publication about the treatment of triple-class refractory multiple myeloma in Spain

We are very pleased to share the latest publication for which OMAKASE is a coauthor. A study to determine the value contribution of belantamab mafodotin (Belamaf) for the treatment of triple-class refractory multiple myeloma in Spain based on MCDA methodology.

The study is based on the determination by a multistakeholder panel of Spanish experts, with the objective to determine, analyse and discuss key unmet needs and relative value contribution of Belamaf compared to two treatment alternatives for this patient population, pomalidomide plus cyclophosphamide and dexamethasone [PomCyDex] and selinexor plus dexamethasone [Selinexor+Dex].

The study has been published in the Revista Española de Economia de la Salud (EDS) (Spanish Health Economics Journal) and can be downloaded here.

#tripleclassrefractory#multiplemyeloma#anti-BCMA#MCDA#Spain

RevEspEconSalud2021.V16N3.58-69_Belantamab-Value-Contribution

2021-07-15T09:36:55+00:00July 15th, 2021|Articles|